Acceleron begins dosing in Phase II trial of ACE-083 to treat CMT

Acceleron Pharma has started dosing patients in a Phase II clinical trial of its therapeutic candidate ACE-083 for the treatment of Charcot-Marie-Tooth disease (CMT) patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news